A Revolutionary Vaccine Based on Messenger RNA Prevented Cancer Recurrence in a Clinical Study
4 Articles
4 Articles
They managed to prevent the recurrence and spread of melanoma in a large clinical trial, using a serum of mRNA; expectations of a new treatment pathway
Moderna's actions rose more than 100%, given the advance of her personalized cancer vaccine.
A cancer vaccine, personalized for each patient, was successful in a large clinical study in the final phase, giving hope that a new generation of personalized treatments could bring benefits to thousands of people, reports The Times.
US pharmaceutical giant Merck and biotechnology company Moderna recently announced that their collaboratively developed personalized mRNA cancer vaccine (intismeran/V940), combined with the anti-cancer drug Keytruda, has met its targets in a large clinical trial involving over 1,000 melanoma patients, potentially reducing the risk of cancer recurrence and metastasis. This experimental therapy is named "Intismeran..."
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
